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Objective:  The  purpose  of  this  study  is to investigate  the  presence  of  a statistical  association  between
epicardial  fat  thickness  (EFT)  and  coronary  artery  disease  (CAD)  and  between  ﬂow-mediated  vasodilation
(FMD)  and  CAD.
Methods: We  measured  the EFT  and  FMD  in  64  subjects  with  suspected  stable  angina  pectoris.  The  patients
were  separated  into  two  groups  according  to  their  coronary  angiography  results:  34 patients  with  CAD
and  30  patients  with  normal  coronary  arteries  (NCA).
Results:  EFT  was  signiﬁcantly  higher  in  the  patients  with  CAD  than  the NCA  group  (6.43 ±  0.90  mm  vs.
5.35  ±  0.75  mm,  p < 0.001)  while  FMD was  signiﬁcantly  lower  in the patients  with  CAD  than  those  in  the
NCA  group  (6.41  ± 2.51%  vs. 8.33  ±  3.45%,  p =  0.015).  No  signiﬁcant  correlation  was  found  between  EFT
and FMD.  After  adjustment  for EFT,  FMD,  age, sex,  ejection  fraction,  glucose,  and  low-density  lipoprotein
cholesterol  through  multivariate  logistic  regression  analysis,  EFT  (odds  ratio:  6.325,  95%  conﬁdence  inter-
val 2.289–17.476,  p < 0.001)  and age  (odds  ratio:  1.093,  95%  conﬁdence  interval  1.008–1.185,  p =  0.032)
remained signiﬁcant  predictors  of CAD.  A  cut-off  value  of EFT  ≥ 5.8  mm  predicted  the  presence  of CAD
with  77%  sensitivity  and  70%  speciﬁcity.
Conclusion:  An  echocardiographic  EFT  assessment  is  independently  associated  with  the  presence  of  CAD.
Thus,  EFT  may  be helpful  in cardiometabolic  risk  stratiﬁcation  and  therapeutic  interventions.
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Epicardial adipose tissue is the source of several endocrine
nd inﬂammatory mediators [1]. Epicardial fat may  play a central
ole in the pathogenesis of cardiovascular disease mediated by
ts inﬂammatory properties [2–5]. Therefore, visceral fat pre-
icts an unfavorable cardiovascular and metabolic risk proﬁle in
umans, and an echocardiographic assessment of epicardial fat
hickness (EFT) is a reliable marker of visceral adiposity. A possible
ssociation between epicardial adipose tissue and atherosclerosis
as been shown in certain recent studies [6–10]. Flow-mediated
asodilation (FMD) evaluates endothelium-dependent vasodila-
ion, is a reliable marker of arterial endothelial dysfunction and
s related to coronary artery disease (CAD). Endothelial dysfunc-
ion results from functional changes, which are characterized
y vasospasm, coagulation abnormalities, and increased vascular
roliferation, and is reported to be the initial step in atherosclerosis
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[11–13]. Peripheral endothelial function can be non-invasively
evaluated by the measurement of the FMD of the brachial artery
using high-resolution ultrasound methods [14,15].
Concomitant evaluation of EFT and FMD  in patients with
suspected stable angina pectoris (SAP) has not previously been
investigated. In this study we  evaluated the EFT and FMD  in subjects
with and without CAD.
Methods
Study population
In this observational study, we enrolled 64 consecutive patients
(40 men, mean age 56.9 ± 11.2 years) with suspected SAP, who
underwent a coronary angiography. The patients’ histories were
recorded, and all patients underwent a complete physical exami-
nation. The patients who had a history of established heart disease,
hypertension, known diabetes, overt liver disease, obesity [body
mass index (BMI) ≥30], cancer, chronic renal disease, alcohol or
drug abuse, and thyroid problems were excluded from the study.
Moreover, those patients whose transthoracic echocardiographic
vier Ltd. All rights reserved.
3 Cardio
i
E
t
c
w
b
C
n
e
b
i
a
C
m
i
3
(
E
i
t
M
f
d
(
t
T
a
i
i
w
r
m
d
o
E
c
a
a
M
f
w
o
c
b
p
a
(
B
p
i
i
a
o
s
i
a
M44 H. Kaya et al. / Journal of 
maging produced inadequate data for the measurement of their
FT were also excluded from the study. All participants underwent
ransthoracic echocardiography and FMD  examinations. Informed
onsent was obtained from all participants in writing, and the study
as conducted based on the approval of the institutional review
oard.
oronary angiography technique and data
Coronary angiographies were performed using the Judkins tech-
ique with femoral artery access, and the angiograms were visually
valuated by two interventional cardiologists, who were blinded
oth to the study plan and each other. A thorough review of each
ndex coronary angiogram established the location of the lesions
nd the percentage of stenosis among all of the coronary lesions.
AD was deﬁned as >50% luminal diameter stenosis of at least one
ajor epicardial coronary artery [16]. The patients were separated
nto two groups according to their coronary angiography results:
4 patients with CAD and 30 patients with normal coronary arteries
NCA).
chocardiogram and epicardial fat measurement
All participants underwent transthoracic echocardiography
maging using an echocardiograph equipped with a broadband
ransducer (Vivid S6, GE Vingmed Ultrasound, Horten, Norway).
easurements were obtained from the long-axis and apical
our-chamber view according to standard criteria. The echocar-
iographic images were entered into a computerized database
EchoPac). The ofﬂine measurements of EFT were performed by
wo cardiologists who were unaware of the patient’s clinical data.
he echocardiograms of 20 patients were randomly selected, and
 second measurement of the EFT was performed two  weeks later
n order to assess the inter-observer and intra-observer variabil-
ty. The inter-observer and intra-observer variabilities of the EFT
ere found to be 3.8% and 3.5%, respectively. The echocardiog-
aphic assessments of the EFT were measured according to the
ethod previously described by Iacobellis et al. [17]. The epicar-
ial fat was identiﬁed as an echo-free space in the pericardial layers
n the two-dimensional echocardiography [18,19]. The maximum
FT was measured at the point on the free wall of the right ventri-
le along the midline of the ultrasound beam, perpendicular to the
ortic annulus. This was determined to be the anatomic landmark
t the end-diastole in three cardiac cycles.
easurement of ﬂow-mediated vasodilation
The ultrasonographic evaluations of the patients’ endothelial
unction and ﬂow-mediated endothelial-dependent vasodilation
ere effectuated by FMD  measurement in the brachial artery
f the non-dominant arm. The validity of the method has been
onﬁrmed in previous studies [20,21]. FMD  test was  performed
efore coronary angiography. An experienced vascular sonogra-
her, who was blinded to the patients’ information, performed
n ultrasound examination using a Vivid S6 Ultrasound System
GE Vingmed Ultrasound) with a 12-MHz linear array transducer.
rieﬂy, the patients were instructed to lie quietly in a supine
osition for 10 min  before the study. All studies were performed
n a temperature-controlled room (20–25 ◦C). Arterial ﬂow was
nterrupted for 5 min  by a cuff placed on the proximal forearm
t whichever occlusion pressure would be higher, i.e. 200 mmHg
r 50 mmHg  + systolic blood pressure. The brachial artery was
canned in a longitudinal section, the focus zone was set to optimize
mages of the lumen–arterial wall interface, and the machine oper-
ting parameters were not changed during the rest of the study.
easurements were taken from the anterior to posterior “m”  linelogy 62 (2013) 343–347
at the end-diastole, incident with the R-wave on the electrocar-
diogram. Three cardiac cycles were analyzed for each scan, and
the measurements were averaged. Arterial diameter was  measured
60 s after cuff deﬂation. Endothelium-dependent, post-ischemic
FMD  was  determined by the maximal brachial artery diameter after
exactly 60 s of reactive hyperemia, compared with the baseline ves-
sel diameter, and was expressed as a percentage of FMD. The two
cardiologists who were blinded to the participants’ clinical data
interpreted the ultrasound results using an ofﬂine method. The
intra- and inter-observer variability of the FMD  were calculated
in 20 patients by plotting the patients’ FMD  estimates from each
measurement against the estimates by two independent measure-
ments. The standard error of the estimate was calculated using this
plot. The intra- and inter-observer variability were 4.6% and 5.3%,
respectively.
Anthromorphometry and laboratory tests
On admission, blood samples were obtained to measure
the patients’ glucose, creatinine, total cholesterol, triglycerides,
low-density lipoprotein-cholesterol (LDL-C), and high-density
lipoprotein-cholesterol levels (HDL-C), which were assayed using
routine laboratory techniques. BMI  was  deﬁned as weight (kg)
divided by the square of height (m), and waist circumference was
recorded as the average of two  measurements while the subject
was standing at midpoint between the lowest rib and the iliac crest.
Statistical analysis
A statistical analysis was  carried out using SPSS for Windows
version 15.0 (SPSS Inc., Chicago, IL, USA). All variables were tested
for the normal distribution using the Kolmogorov–Smirnov test.
Continuous variables were expressed as mean ± SD, and categorical
variables were expressed as numbers and percentages. Student’s
t-test or the Mann–Whitney U-test were used for the continuous
variables, and the 2 test was used for the categorical changes. The
relationships between the variables were examined with Pearson’s
correlation coefﬁcients. The cut-off value of the EFT for predicting
the presence of CAD with corresponding sensitivity and speciﬁcity
was estimated by the receiver operating characteristic (ROC) curve
analysis. Conventional risk factors of CAD (age, gender, glucose, and
LDL-C) and all variables showing signiﬁcance values p < 0.1 on uni-
variate analysis (EFT, FMD, and ejection fraction) were included in
the multivariate model. Statistical signiﬁcance was based on a value
of p < 0.05.
Results
The clinical and laboratory characteristics are shown in Table 1.
All clinical and anthropometric parameters, except EFT and FMD,
were similar between the two  groups. EFT was  signiﬁcantly higher
in the patients with CAD than the NCA group (6.43 ± 0.90 mm
vs. 5.35 ± 0.75 mm,  p < 0.001). FMD  was  signiﬁcantly lower in the
patients with CAD than those in the NCA group (6.41 ± 2.51% vs.
8.33 ± 3.45%, p = 0.015). Both groups were similar in terms of bio-
chemical analysis. No signiﬁcant correlation was  found between
EFT and FMD  in the whole sample (r = −0.232, p = 0.065), in patients
with CAD (r = 0.052, p = 0.771), and in patients with NCA (r = −0.209,
p = 0.267).
After adjustment for EFT, FMD, age, sex, ejection fraction,
glucose, and LDL-cholesterol through multivariate logistic regres-
sion analysis, EFT (odds ratio: 6.325, 95% conﬁdence interval
2.289–17.476, p < 0.001) and age (odds ratio: 1.093, 95% conﬁdence
interval 1.008–1.185, p = 0.032) remained signiﬁcant predictors of
CAD whereas the adjusted association between FMD  and CAD was
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Table  1
Baseline characteristics of patients in the NCA and CAD groups.
NCA (n = 30) CAD (n = 34) p-Value*
Mean age (years) 54.8 ± 10.3 58.7 ± 11.8 0.168
Male, n (%) 16 (53) 24 (70) 0.155
Waist circumference (cm) 83.4 ± 9.0 84.8 ± 8.2 0.520
BMI  (g/m2) 26.0 ± 3.3 26.1 ± 2.8 0.953
Smoking, n (%) 5 (17) 6 (18) 0.917
Systolic blood pressure (mmHg) 116.8 ± 11.9 116.8 ± 11.9 0.982
Diastolic blood pressure (mmHg) 71.3 ± 8.0 72.4 ± 7.5 0.602
Ejection fraction (%) 60.5 ± 3.3 58.5 ± 3.8 0.053
Glucose (mg/dl) 100.0 ± 13.2 101.2 ± 12.7 0.702
Creatinine (mg/dl) 0.8 ± 0.2 0.8 ± 0.2 0.242
Total cholesterol (mg/dl) 185.0 ± 39.1 185.9 ± 43.5 0.937
LDL-cholesterol (mg/dl) 106.0 ± 31.8 117.0 ± 36.3 0.205
HDL-cholesterol (mg/dl) 37.5 ± 10.0 36.3 ± 8.9 0.639
Triglycerides (mg/dl) 202.4 ± 124.9 162.5 ± 73.6 0.133
Epicardial fat thickness (mm)  5.35 ± 0.75 6.43 ± 0.90 <0.001
Flow mediated vasodilation (%) 8.33 ± 3.45 6.41 ± 2.51 0.015
Abbreviations: NCA, normal coronary artery; CAD, coronary artery disease; BMI, body
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alues are given as mean ± SD or n (%).
* Student’s t-test; Mann–Whitney U-test; Chi-square test.
ot statistically signiﬁcant (p = 0.057) (Table 2). Using ROC anal-
sis, a level of EFT ≥ 5.8 predicted the presence of CAD with 77%
ensitivity and 70% speciﬁcity (ROC area under curve = 0.823, 95%
onﬁdence interval = 0.723–0.922, p < 0.001) (Fig. 1).
iscussion
The present study demonstrated that increased levels of EFT
re an independent predictor for the presence of CAD. In addition,
MD  was signiﬁcantly lower in the patients with CAD than those in
he NCA group, whereas in the multivariate analysis, FMD  was  not
ound to be a predictor of CAD. Moreover, our study showed that a
evel of EFT ≥ 5.8 mm predicted the presence of CAD with 77% sen-
itivity and 70% speciﬁcity. To the best of our knowledge, this is the
rst study to report on the concomitant relationship between the
FT, FMD, and CAD.
Epicardial fat is thought to promote the development and
rogression of coronary atherosclerosis. Elevated inﬂammatory
nﬁltrate has been described in the epicardial fat of subjects with
AD [1]. The paracrine or vasocrine secretion of epicardial inﬂam-
atory molecules contributes to the metabolic and inﬂammatory
ilieu that also promotes atherogenesis [1]. In vitro studies have
hown that the paracrine dialogs between human adipocytes
nd the inﬂammatory cells present in adipose tissue promote an
ncreased synthesis of numerous biomolecules, leading to a low-
rade inﬂammatory microenvironment [5]. These conditions most
ikely promote plaque formation and coronary stenosis.Recently, scientiﬁc and clinical interest in epicardial fat has
ncreased [22–25]. The study by Shemirani and Khoshavi [26]
ighlights the correlation between echocardiographic EFT and the
able 2
ultivariate logistic regression analysis to assess predictors of presence of coronary
rtery disease.
Odds ratio 95% conﬁdence interval p-Value
EFT 6.325 2.289–17.476 <0.001
FMD  0.763 0.577–1.009 0.057
Age  1.093 1.008–1.185 0.032
Sex  5.030 0.949–26.666 0.058
Ejection fraction 0.895 0.710–1.128 0.346
Glucose 0.965 0.904–1.030 0.288
LDL-cholesterol 1.017 0.995–1.040 0.132
bbreviations: EFT; epicardial fat thickness; FMD; ﬂow mediated vasodilation; LDL;
ow density cholesterol.Fig. 1. Receiver operating characteristic (ROC) curve analysis of the epicardial fat
thickness level predicting coronary artery disease in patients with stable angina.
severity of coronary artery disease. Ahn et al. [27] showed that
EFT was thicker in subjects with CAD than in those without CAD
and that it might provide additional information for assessing CAD
risk and predicting the extent and activity of CAD. The results of
Comert et al. [28] found a signiﬁcant correlation between slow
coronary ﬂow, deﬁned as an early phase of atherosclerosis, and
EFT while Iacobellis and Sharma [24] showed that an echocardi-
ographic assessment of epicardial fat can serve as a new index of
cardiac and visceral adiposity. Moreover, epicardial fat is known
to be clinically correlated with abdominal visceral adiposity mea-
sured by the echocardiographic presence of atherosclerosis [29,30]
and CAD [31].
Endothelial dysfunction promotes CAD and has been shown
to precede angiographic or ultrasonic evidence of atheroscle-
rosis [12,32,33]. In patients with endothelial dysfunction, the
balance between vasoconstriction and vasodilation is disturbed,
and permeability, platelet aggregation, leukocyte adhesion, and the
generation of cytokines are increased [34–36]. Endothelial dysfunc-
tion is frequently present in patients presenting with stable CAD.
FMD  evaluates endothelium-dependent vasodilation, is a reliable
marker of arterial endothelial dysfunction, and is related to CAD. It
provides important prognostic data in addition to more traditional
cardiovascular risk factors from which FMD has been used to eval-
uate endothelial function [37–39]. A decreased FMD  value could be
one of the predictors of CAD in patients with stable angina. This
result agrees with a previous report that showed impaired FMD  to
be a marker of the preclinical phase of overt CAD [33].
The main difference between our study population and previous
cohorts was the inclusion of patients with only SAP. Comorbidi-
ties and medication that could interfere with FMD  values were
excluded, and this enables a better evaluation of FMD  and SAP. Fur-
thermore, FMD  and EFT have not been simultaneously evaluated
in patients with CAD. A previous study, conducted by Mazzoccoli
et al. [40] of patients with idiopathic deep vein thrombosis found
impaired FMD  and increased EFT thickness. The authors concluded
that these alterations might predict an increased risk of cardiovas-
cular events.The epicardial adipose tissue reﬂects the visceral adiposity,
which has been proposed as a new cardiometabolic risk factor
[22]. Epicardial fat may  play a central role in the pathogenesis
3 Cardio
o
[
a
w
f
a
E
t
l
l
a
d
i
t
e
t
d
E
p
a
v
w
o
S
s
m
g
a
v
t
l
t
a
C
a
i
F
e
m
s
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[46 H. Kaya et al. / Journal of 
f cardiovascular disease mediated by its inﬂammatory properties
2–5]. FMD  is a reliable marker of arterial endothelial dysfunction
nd is related to CAD. The aim of this study was  to investigate
hether two markers of cardiovascular risk (FMD and epicardial
at) were associated with CAD. Although, FMD  and EFT were
ssociated with CAD, we could not ﬁnd any relationship between
FT and FMD.
Endothelial dysfunction and epicardial adipose tissue contribute
o risk assessment possibly in different ways reﬂecting a cumu-
ative risk associated with CAD. Increased pericoronary fat and
ocal visceral adipose tissue may  increase the development of
therosclerosis in the underlying coronary vasculature. Epicar-
ial adipose tissue secretes proinﬂammatory mediators including
nterleukin-1B, interleukin-6, monocyte chemotactic protein, and
umor necrosis factor, and promotes CD45 mRNA expression with
levated macrophage and mast cell inﬁltration in the adventi-
ia of coronary lesions [1,41,42]. Therefore, epicardial fat may
irectly promote regional atherosclerosis from the adventitial side.
ndocrine effect through adventitial vasa vasorum, and direct
aracrine effect that atherogenic signals diffuse in interstitial ﬂuid
cross the vessel wall may  be a reason for the greater predictive
alue of fat thickness in detecting CAD. As a result, EFT and age
ere better predictors of the presence of CAD than FMD  or the
ther coronary risk factors in patients with SAP.
tudy limitations
Our study has several limitations. We  included subjects meeting
peciﬁc criteria of inclusion. This allowed us to compare well-
atched groups, but the results obtained may  not be applied to the
eneral population. Echocardiographic EFT is a linear measurement
nd therefore may  not reﬂect the total epicardial fat volume that
aries at different locations around the myocardium. We  believe
hat echocardiography is accurate, easier, readily available, and
ess expensive than magnetic resonance imaging and computed
omography which are the gold standard diagnostic methods for
ssessing EFT and volumes.
onclusion
Increased EFT and altered endothelium-dependent vasodilation
re markers of increased cardiovascular risk. The data obtained
n our study show that subjects with SAP have an impairment of
MD  and an increase in EFT. EFT was a better predictor of the pres-
nce of CAD than FMD  in patients with SAP. The evaluation of EFT
ight represent valuable and reliable tools to reﬁne clinical risk
tratiﬁcation in patients with CAD.
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